Pixium Vision (PAR: PIX)

Last close As at 21/12/2024

EUR0.15

−0.04 (−21.05%)

Market capitalisation

EUR1m

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for Dry-ARMD. The company has completed a human feasibility study for Prima in Europe and expects to start implantations in a US feasibility study in H119.

Latest Insights

View More

Healthcare | Flash note

Pixium Vision — Safeguard proceedings underway

Healthcare | Update

Pixium Vision — Shareholder loan extends runway

Healthcare | Flash note

Pixium Vision — Breakthrough designation provides validation

Pixium-Vision_resized

Further insights

insight

Healthcare

Retinal implants

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free